

WILLIAM H. MILLER, PH.D.

Collegeville, PA 19426
+1 (610) 724-1618
whmiller@medchem-innovations.com

<https://medchem-innovations.com>
www.linkedin.com/in/william-h-miller

PUBLICATIONS

1. Miller, W. H.; Ryckman, D. M.; Goekjian, P. G.; Wang, Y.; Kishi, Y. Preferred conformation of C-glycosides. 5. Experimental support for the conformational similarity between C- and O-disaccharides. *J. Org. Chem.* 1988, 53, 5580-5582.
2. Wang, Y.; Goekjian, P. G.; Ryckman, D. M.; Miller, W. H.; Babirad, S. A.; Kishi, Y. Preferred conformation of C-glycosides. 9. Conformational analysis of 1,4-linked carbon disaccharides. *J. Org. Chem.* 1992, 57, 482-489.
3. Ku, T. W.; Ali, F. E.; Barton, L. S.; Bean, J. W.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, L.; Eggleston, D. S.; Gleason, J. G.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Karash, C. B.; Keenan, R. M.; Kopple, K. D.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Peishoff, C. E.; Samanen, J. M.; Uzinskas, I.; Venslavsky, J. W. Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide. *J. Am. Chem. Soc.* 1993, 115, 8861-8862.
4. Kress, M. H.; Ruel, R.; Miller, W. H.; Kishi, Y. Synthetic studies toward the taxane class of natural products. *Tetrahedron Lett.* 1993, 34, 5999-6002.
5. Kress, M. H.; Ruel, R.; Miller, W. H.; Kishi, Y. Investigations of the intramolecular Ni(II)/Cr(II)-mediated coupling reaction: application to the taxane ring system. *Tetrahedron Lett.* 1993, 34, 6003-6006.
6. Miller, W. H.; Pinto, D. J. P.; McHugh, R. J., Jr.; Arner, E. C.; Pratta, M. A.; Magolda, R. L. Inhibition of cartilage degradation by isothiazoloquinolinones. *Bioorg. Med. Chem. Lett.* 1994, 4, 843.
7. Bondinell, W. E.; Keenan, R. M.; Miller, W. H.; Ali, F. E.; Allen, A. C.; DeBrosse, C. W.; Eggleston, D. S.; Erhard, K. F.; Haltiwanger, R. C.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Koster, P. F.; Ku, T. W.; Lee, C. P.; Nichols, A. J.; Ross, S. T.; Samanen, J. M.; Valocik, R. E.; Vasko-Moser, J. A.; Venslavsky, J. W.; Wong, A. S.; Yuan, C.-K. Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. *Bioorg. Med. Chem.* 1994, 2, 897-908.
8. Ku, T. W.; Miller, W. H.; Bondinell, W. E.; Keenan, R. M.; Nichols, A. J.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Huffman, W. F. Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore. *J. Med. Chem.* 1995, 38, 9-12.
9. Miller, W. H.; Newlander, K. A.; Eggleston, D. S.; Haltiwanger, R. C. Synthesis of a 2-benzazepine analog of a potent, nonpeptide GPIIb/IIIa antagonist. *Tetrahedron Lett.*, 1995, 36, 373-376.
10. Miller, W. H.; Ku, T. W.; Ali, F. E.; Bondinell, W. E.; Calvo, R. R.; Davis, L. D.; Erhard, K. F.; Hall, L. B.; Huffman, W. F.; Keenan, R. M.; Kwon, C.; Newlander, K. A.; Ross, S. T.; Samanen, J. M.; Takata, D. T.; Yuan, C.-K. Enantiospecific synthesis of SB 214857, a potent, orally active, nonpeptide fibrinogen receptor antagonist. *Tetrahedron Lett.* 1995, 36, 9433-9436.
11. Samanen, J.; Ali, F. E.; Barton, L.; Bondinell, W.; Burgess, J.; Callahan, J.; Calvo, R.; Chen, W.; Chen, L.; Erhard, K.; Heyes, R.; Hwang, S.-M.; Jakas, D.; Keenan, R.; Ku, T.; Kwon, C.; Lee, C.-P.; Miller, W.; Newlander, K.; Nichols, A.; Peishoff, C.; Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Yellin, T. O.; Uzinskas, I.; Venslavsky, J.; Wong, A.; Yuan, C.-K.; Huffman, W. GPIIb/IIIa antagonists with long oral duration designed from cyclic peptides. In *The Proceedings of the 14th American Peptide Symposium*

- (Peptides: Chemistry, Structure and Biology); Kaumaya, P. T. P., Hodges, R. S., Eds.; Mayflower Scientific: Kingswinford, England, 1996, pp 679-681.
12. Miller, W. H.; Ali, F. E.; Bondinell, W. E.; Callahan, J. F.; Calvo, R. R.; Eggleston, D. S.; Haltiwanger, R. C.; Huffman, W. F.; Hwang, S.-M.; Jakas, D. R.; Keenan, R. M.; Koster, P. F.; Ku, T. W.; Kwon, C.; Newlander, K. A.; Nichols, A. J.; Parker, M. F.; Samanen, J. M.; Southall, L. S.; Takata, D. T.; Uzinskas, I. N.; Valocik, R. E.; Vasko-Moser, J. A.; Wong, A. S.; Yellin, T. O.; Yuan, C. C. K. Structure-activity relationships in 3-oxo-1,4-benzodiazepine-2-acetic acid GPIIb/IIIa antagonists. The 2-benzazepine series. *Bioorg. Med. Chem. Lett.* 1996, 6, 2481-2486.
 13. Samanen, J. M.; Ali, F. E.; Barton, L. S.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, W.; Chen, L.; Erhard, K.; Feuerstein, G.; Heys, R.; Hwang, S. -M.; Jakas, D. R.; Keenan, R. M.; Koster, P. F.; Ku, T. W.; Kwon, C.; Lee, C. -P.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M.; Peishoff, C. E.; Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Vasko-Moser, J. A.; Valocik, R. E.; Yellin, T. O.; Uzinskas, I.; Venslavsky, J. W.; Wong, A.; Yuan, C. -K.; Huffman, W. F. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. *J. Med. Chem.* 1996, 39, 4867-4870.
 14. Keenan, R. M.; Miller, W. H.; Kwon, C.; Ali, F. E.; Callahan, J. F.; Calvo, R. R.; Hwang, S. M.; Kopple, K. D.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Yuan, C. K.; Huffman, W. F. Discovery of potent nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonists. *J. Med. Chem.* 1997, 40, 2289-2292.
 15. Keenan, R. M.; Miller, W. H.; Lago, M. A.; Ali, F. E.; Bondinell, W. E.; Callahan, J. F.; Calvo, R. R.; Cousins, R. D.; Hwang, S.-M.; Jakas, D. R.; Ku, T. W.; Kwon, C.; Nguyen, T. T.; Reader, V. A.; Rieman, D. J.; Ross, S. T.; Takata, D. T.; Uzinskas, I. N.; Yuan, C. C. K.; Smith, B. R. Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonists. *Bioorg. Med. Chem. Lett.* 1998, 8, 3165-3170.
 16. Keenan, R. M.; Lago, M. A.; Miller, W. H.; Ali, F. E.; Cousins, R. D.; Hall, L. B.; Hwang, S.-M.; Jakas, D. R.; Kwon, C.; Loudon, C.; Nguyen, T. T.; Ohlstein, E. H.; Rieman, D. J.; Ross, S. T.; Samanen, J. M.; Smith, B. R.; Stadel, J.; Takata, D. T.; Vickery, L.; Yuan, C. C. K.; Yue, T.-L. Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonist with efficacy in a restenosis model. *Bioorg. Med. Chem. Lett.* 1998, 8, 3171-3176.
 17. Keenan, R. M.; Callahan, J. F.; Samanen, J. M.; Bondinell, W. E.; Calvo, R. R.; Chen, L.; DeBrosse, C.; Eggleston, D. S.; Haltiwanger, R. C.; Hwang, S.-M.; Jakas, D. R.; Ku, T. W.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Southall, L. S.; Uzinskas, I.; Vasko-Moser, J. A.; Venslavsky, J. W.; Wong, A. S.; Huffman, W. F. Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists. *J. Med. Chem.* 1999, 42, 545-559.
 18. Keenan, R. M.; Miller, Barton, L. S.; W. H.; Bondinell, W. E.; Cousins, R. D.; Eppley, D. F.; Hwang, S.-M.; Kwon, C.; Lago, M. A.; Nguyen, T. T.; Smith, B. R.; Uzinskas, I. N.; Yuan, C. C. K. Nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics. *Bioorg. Med. Chem. Lett.* 1999, 9, 1801-1806.
 19. Miller, W. H.; Bondinell, W. E.; Cousins, R. D.; Erhard, K. F.; Jakas, D. R.; Keenan, R. M.; Ku, T. W.; Newlander, K. A.; Ross, S. T.; Haltiwanger, R. C.; Bradbeer, J.; Drake, F. H.; Gowen, M.; Hoffman, S. J.; Hwang, S.-M.; James, I. E.; Lark, M. W.; Lechowska, B.; Rieman, D. J.; Stroup, G. B.; Vasko-Moser, J. A.; Zembryki, D. L.; Azzarano, L. M.; Adams, P. C.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Johanson, K. O.; Huffman, W. F. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. *Bioorg. Med. Chem. Lett.* 1999, 9, 1807-1812.
 20. Lark, M. W.; Stroup, G. B.; Hwang, S.-M.; James, I. E.; Rieman, D. J.; Drake, F. H.; Bradbeer, J.; Mathur, A.; Karl F. Erhard, K. F.; Newlander, K. A.; Ross, S. T.; Salyers, K. L.; Smith, B. R.; Miller, W. H.; Huffman, W. F.; Gowen, M. Design and characterization of an orally active Arg-Gly-Asp peptidomimetic

- vitronectin receptor antagonist, SB 265123, for the prevention of bone loss in osteoporosis. *J. Pharm. Exp. Ther.* 1999, 291, 612-617.
21. Ward, K. W.; Azzarano, L. M.; Bondinell, W. E.; Cousins, R. D.; Huffman, W. F.; Jakas, D. R.; Keenan, R. M.; Ku, T. W.; Lundberg, D.; Miller, W. H.; Mumaw, J. A.; Newlander, K. A.; Pirhalla, J. L.; Roethke, T. J.; Salyers, K. L.; Souder, P. R.; Stelman, G. J.; Smith, B. R. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. *Drug Metabolism and Disposition* 1999, 27, 1232-1241.
 22. Miller, W. H.; Alberts, D. P.; Bhatnagar, P. K.; Bondinell, W. E.; Callahan, J. F.; Calvo, R. R.; Cousins, R. D.; Erhard, K. F.; Heerding, D. A.; Keenan, R. M.; Kwon, C.; Manley, P. J.; Newlander, K. A.; Ross, S. T.; Samanen, J. M.; Uzinskas, I. N.; Venslavsky, J. W.; Yuan, C. C. K.; Haltiwanger, R. C.; Gowen, M.; Hwang, S.-M.; James, I. E.; Lark, M. W.; Rieman, D. J.; Stroup, G. B.; Azzarano, L. M.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Johanson, K. O.; Huffman, W. F. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. *J. Med. Chem.* 2000, 43, 22-26.
 23. Miller, W. H.; Keenan, R. M.; Willette, R. N.; Lark, M. W. Identification and in vivo efficacy of small molecule antagonists of integrin $\alpha v \beta 3$ (the vitronectin receptor). *Drug Discovery Today*, 2000, 5, 397-408.
 24. Badger, A. M.; Blake, S.; Kapadia, R.; Sarkar, S.; Levin, J.; Swift, B. A.; Hoffman, S. J.; Stroup, G. B.; Miller, W. H.; Gowen, M.; Lark, M. W. Disease-modifying activity of SB 273005, an orally active, nonpeptide $\alpha v \beta 3$ (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. *Arthritis and Rheumatism* 2001, 44, 128-137.
 25. Lark, M. W.; Stroup, G. B.; Dodds, R. A.; Kapadia, R.; Hoffman, S. J.; Hwang, S. M.; James, I. E.; Lechowska, B.; Liang, X.; Rieman, D. J.; Salyers, K. L.; Ward, K.; Smith, B. R.; Miller, W. H.; Huffman, W. F.; Gowen, M. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. *J. Bone Min. Res.*, 2001, 16, 319-327.
 26. Heerding, D. A.; Chan, G.; DeWolf, W. E., Jr.; Fosberry, A. P.; Janson, C. A.; Jaworski, D. D.; McManus, E.; Miller, W. H.; Moore, T. D.; Payne, D. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Smith, W.; Takata, D. T.; Vaidya, K. S.; Yuan, C. C. K.; Huffman, W. F. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). *Bioorg. Med. Chem. Lett.* 2001, 11, 2061-2065.
 27. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; DeWolf, W. E., Jr.; Keller, P. M.; Qiu, X.; Janson, C. A.; Vaidya, K.; Fosberry, A. P.; Smyth, M. G.; Jaworski, D. D.; Slater-Radosti, C.; Huffman, W. F. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents. *Bioorg. Med. Chem. Lett.*, 2001, 11, 2241-2244.
 28. Hoffman, S. J.; Vasko-Moser, J.; Miller, W. H.; Lark, M. W.; Gowen, M.; Stroup, G. Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist. *J. Pharm. Exp. Ther.* 2002, 302, 205-211.
 29. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Heerding, D. A.; Yuan, C. C. K.; Head, M. S.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; Pearson, S. C.; Berry, V.; DeWolf, W. E., Jr.; Keller, P. M.; Polizzi, B. J.; Qiu, X.; Janson, C. A.; Huffman, W. F. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). *J. Med. Chem.* 2002, 45, 3246-3256.
 30. Payne, D. J.; Miller, W. H.; Berry, V.; Brosky, J.; Burgess, W. J.; Chen, E.; DeWolf, W. E., Jr.; Fosberry, A. P.; Greenwood, R.; Head, M. S.; Heerding, D. A.; Janson, C. A.; Jaworski, D. D.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Newlander, K. A.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Salyers, K. L.; Seefeld, M. A.; Smyth, M. G.; Takata, D. T.; Uzinskas, I. N.; Vaidya, K.; Wallis, N. G.;

- Winram, S. B.; Yuan, C. C. K.; Huffman, W. F. Discovery of a novel and potent class of FabI directed antibacterial agents. *Antimicrob. Agents Chemother.* 2002, 46, 3118-3124.
31. Fan, F.; Yan, K.; Wallis, N. G.; Reed, S.; Moore, T. D.; Rittenhouse, S. F.; DeWolf, W. E., Jr.; Huang, J.; McDevitt, D.; Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Jakas, D. R.; Head, M. S.; Payne, D. J. Defining and combating the mechanisms of triclosan resistance in clinical isolates of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 2002, 46, 3343-3347.
32. Miller, W. H.; Manley, P. J.; Cousins, R. D.; Erhard, K. F.; Heerding, D. A.; Kwon, C.; Ross, S. T.; Samanen, J. M.; Takata, D. T.; Uzinskas, I. N.; Yuan, C. C. K.; Haltiwanger, R. C.; Gress, C. J.; Lark, M. W.; Hwang, S.-M.; James, I. E.; Rieman, D. J.; Willette, R. N.; Yue, T.-L.; Azzarano, L. M.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Johanson, K. O.; Huffman, W. F. Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin $\alpha v \beta 3$) antagonists. *Bioorg. Med. Chem. Lett.*, 2003, 13, 1483-1486.
33. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; DeWolf, W. E., Jr.; Elkins, P. A.; Head, M. S.; Jakas, D. R.; Janson, C. A.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Payne, D. J.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Uzinskas, I. N.; Wallis, N. G.; Huffman, W. F. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. *J. Med. Chem.* 2003, 46, 1627-1635.
34. Medina, J.; Blackledge, C.; Erhard, K.; Axten, J.; Miller, W. Benzyl 2-cyano-3,3-dimethyl-1-pyrrolidinecarboxylate, a versatile intermediate for the synthesis of 3,3-dimethylproline derivatives. *J. Org. Chem.* 2008, 73(10), 3946-3949.
35. Rouse, M. B.; Seefeld, M. A.; Heerding, D. A.; Leber, J. D.; Miller, W. H.; Rhodes, N.; Kumar, R.; Choudhry, A. E.; Concha, N. O.; Lai, Z.; McNulty, K. C.; Minthorn, E. A.; Schaber, M. D.; Sun, L.; Warren, G. L.; Zhang, S. Y. Aminofurazans as potent inhibitors of AKT kinase. *Bioorg. Med. Chem. Lett.* 2009, 19(5), 1508-1511.
36. Medina, J. R.; Grant, S. W.; Axten, J. M.; Miller, W. H.; Donatelli, C. A.; Hardwicke, M. A.; Oleykowski, C. A.; Liao, Q.; Plant, R.; Xiang, H. Discovery of a new series of aurora inhibitors through truncation of GSK1070916. *Bioorg. Med. Chem. Lett.* 2010, 20(8), 2552-2555.
37. Medina, J. R.; Becker, C. J.; Blackledge, C. W.; Duquette, C.; Feng, Y.; Grant, S. W.; Heerding, D.; Li, W. H.; Miller, W. H.; Romeril, S. P.; Scherzer, D.; Shu, A.; Bobko, M. A.; Chadderton, A. R.; Dumble, M.; Gardiner, C. M.; Gilbert, S.; Liu, Q.; Rabindran, S. K.; Sudakin, V.; Xiang, H.; Brady, P. G.; Campobasso, N.; Ward, P.; Axten, J. M. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. *J. Med. Chem.* 2011, 54(6), 1871-95.
38. Miles, T. J.; Axten, J. M.; Barfoot, C.; Brooks, G.; Brown, P.; Chen, D.; Dabbs, S.; Davies, D. T.; Downie, D. L.; Eyrish, S.; Gallagher, T.; Giordano, I.; Gwynn, M. N.; Hennessy, A.; Hoover, J.; Huang, J.; Jones, G.; Markwell, R.; Miller, W. H.; Minthorn, E. A.; Rittenhouse, S.; Seefeld, M.; Pearson, N. Novel amino-piperidines as potent antibacterials targeting bacterial type II topoisomerases. *Bioorg. Med. Chem. Lett.* 2011, 21, 7489-7495.
39. Axten, J. M.; Medina, J. R.; Blackledge, C. W.; Duquette, C.; Grant, S. W.; Bobko, M. A.; Peng, T.; Miller, W. H.; Pinckney, T.; Gallagher, T. F.; Kulkarni, S.; Lewandowski, T.; Van Aller, G. S.; Zonis, R.; Ward, P.; Campobasso, N. Acylprolinamides: A new class of peptide deformylase inhibitors with in vivo antibacterial activity. *Bioorg. Med. Chem. Lett.* 2012, 22(12), 4028-4032.
40. McCabe, M. T.; Ott, H. M.; Ganji, G.; Korenchuk, S.; Thompson, C.; Van Aller, G. S.; Liu, Y.; Graves, A. P.; Della Pietra III, A.; Diaz, E.; LaFrance, L. V.; Mellinger, M.; Duquette, C.; Tian, X.; Kruger, R. G.; McHugh, C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.; Tummino, P. J.; Creasy, C. L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature* 2012, 492, 108-112.
41. Verma, S.; Tian, X.; LaFrance, L. V.; Duquette, C.; Suarez, D. P.; Newlander, K. A.; Romeril, S. P.; Burgess, J.; Grant, S. W.; Brackley, J. A.; Scherzer, D. A.; Shu, A.; Graves, A. P.; Thompson, C. S.; Ott, H.;

- Van Aller, G. S.; Machutta, C.; Johnson, N. W.; Knight, S. D.; Kruger, R. G.; McCabe, M. T.; Dhanak, D.; Tummino, P.; Creasy, C. L.; Miller, W. H. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. *ACS Med. Chem. Lett.* 2012, 3(12), 1091–1096.
42. Van Aller, G. S.; Pappalardi, M. B.; Ott, H. M.; Diaz, E.; Brandt, M.; Schwartz, B. J.; Miller, W. H.; Dhanak, D.; McCabe, M. T.; Verma, S. K.; Creasy, C. L.; Tummino, P. J.; Kruger, R. G. Long Residence Time Inhibition of EZH2 in Activated Polycomb Repressive Complex 2. *ACS Chemical Biology* 2014, 9(3), 622-629.
43. Mohammad, H. P.; Smitheman, K. N.; Kamat, C. D.; Soong, D.; Federowicz, K. E.; Van Aller, G. S.; Schneck, J. L.; Carson, J. D.; Liu, Y.; Butticello, M.; Bonnette, W. G.; Gorman, S. A.; Degenhardt, Y.; Bai, Y.; McCabe, M. T.; Pappalardi, M. B.; Kaspavec, J.; Tian, X.; McNulty, K. C.; Rouse, M.; McDevitt, P.; Ho, T.; Crouthamel, M.; Hart, T. K.; Concha, N. O.; McHugh, C. F.; Miller, W. H.; Dhanak, D.; Tummino, P. J. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. *Cancer Cell* 2015, 28(1), 57-69.

PRESENTATIONS

1. Miller, W. H.; Bondinell, W. E.; Keenan, R. M.; Ku, T. W.; Newlander, K. A.; Samanen, J. M.; Hwang, S.-M.; Wong, A. S.; Koster, P. F.; Nichols, A. J.; Valocik, R. E.; Vasko-Moser, J. A.; Eggleston, D. S.; Haltiwanger, R. C. 2-benzazepine-4-acetic acid derivatives as fibrinogen receptor antagonists. Poster presentation at the Medicinal Chemistry Gordon Conference, New London, NH, August 7-12, 1994.
2. Miller, W.; Ali, F. E.; Barton, L.; Bondinell, W.; Burgess, J.; Callahan, J.; Calvo, R.; Chen, L.; Erhard, K.; Hwang, S.-M.; Jakas, D.; Keenan, R.; Ku, T.; Kwon, C.; Lee, C.-P.; Newlander, K.; Nichols, A.; Parker, M.; Peishoff, C.; Rhodes, G.; Ross, S.; Samanen, J.; Simpson, R.; Takata, D.; Yellin, T. O.; Uzinskas, I.; Venslavsky, J.; Yuan, C.-K.; Huffman, W. Orally active nonpeptide GPIIb/IIIa antagonists designed from cyclic peptides. Oral presentation at the Western Biotech Conference, San Diego, CA, October 18-21, 1995.
3. Miller, W.; Keenan, R.; Ali, F.; Bondinell, W.; Burgess, J.; Callahan, J.; Calvo, R.; Cousins, R.; Gowen, M.; Huffman, W.; Hwang, S.; Jakas, D.; Ku, T.; Kwon, C.; Lago, A.; Nguyen, T.; Reader, V.; Ross, S.; Samanen, J.; Southall, L.; Takata, D.; Uzinskas, I.; Venslavsky, J.; Wong, A.; Yellin, T.; Yuan, C. Nonpeptide vitronectin receptor antagonists. Oral presentation at the Fourth Annual Development of Small Molecule Mimetic Drugs Conference, Washington, D.C., May 2-3, 1996.
4. Miller, W.; Keenan, R.; Ali, F.; Bondinell, W.; Burgess, J.; Callahan, J.; Calvo, R.; Cousins, R.; Gowen, M.; Huffman, W.; Hwang, S.; Jakas, D.; Ku, T.; Kwon, C.; Lago, A.; Nguyen, T.; Reader, V.; Ross, S.; Samanen, J.; Southall, L.; Takata, D.; Uzinskas, I.; Venslavsky, J.; Wong, A.; Yellin, T.; Yuan, C. Nonpeptide vitronectin receptor antagonists. Poster presentation at the XIVth International Symposium on Medicinal Chemistry, Maastricht, the Netherlands, September 8-12, 1996.
5. Miller, W. H.; Keenan, R. M.; Ali, F. E.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Cousins, R. D.; Gowen, M.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; James, I. E.; Ku, T. W.; Kwon, C.; Lago, M. A.; Nguyen, T. T.; Reader, V. A.; Ross, S. T.; Samanen, J. M.; Southall, L. S.; Stadel, J. M.; Takata, D. T.; Uzinskas, I. N.; Venslavsky, J. W.; Wong, A. S.; Yuan, C.; Yue, T. L.; Zembryki, D. Nonpeptide vitronectin receptor antagonists. Oral presentation at the Lead Generation and Optimization Conference, Princeton, NJ, September 18-19, 1996.
6. Miller, W. H.; Bondinell, W. E.; Cousins, R. D.; Erhard, K. F.; Keenan, R. M.; Newlander, K. A.; Ross, S. T.; Samanen, J. M.; Bradbeer, J.; Drake, F. H.; Hoffman, S. J.; Hwang, S. M.; James, I. E.; Lark, M. W.; Lechowska, B.; Lee-Rykaczewski, E.; Stroup, G. B.; Zembryki, D. L.; Yue, T.-L.; Smith, B. R.; Gowen, M.; Huffman, W. F. The discovery of orally active nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonists. Oral presentation at the 215th ACS National Meeting, Dallas, TX, March 29-April 2, 1998.

7. Miller, W. H.; Cousins, R. D.; Erhard, K. F.; Haltiwanger, R. C.; Keenan, R. M. Newlander, K. A.; Ross, S. T.; Bradbeer, J.; Drake, F. H.; Gowen, M.; Hoffman, S. J.; Hwang, S. M.; James, I. E.; Lark, M. W.; Lechowska, B.; Lee-Rykaczewski, E.; Stroup, G. B.; Vasko-Moser, J. A.; Zembryki, D. L.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Huffman, W. F. The discovery of orally active nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonists. Oral presentation at the 3rd Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 23-29, 1999.
8. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Manley, P. J.; Heerding, D. A.; Takata, D. T.; Yuan, C. C. K.; Head, M. S.; Berry, V.; Greenwood, R.; Jaworski, D. D.; Jepras, R. I.; Moore, T. D.; Payne, D. J.; Pearson, S. C.; Rittenhouse, S. F.; Slater-Radosti, C. E.; Straub, R. J.; Wallis, N. G.; DeWolf, W. E., Jr.; Keller, P. M.; Jansen, C. A.; Qiu, X.; Chen, E.; Salyers, K. L.; Vaidya, K.; Fosberry, A. P.; Smyth, M. G.; Huffman, W. F. Inhibitors of bacterial enoyl-ACP reductase (FabI) 1: Discovery of a novel aminopyridine-based FabI inhibitor with in vivo antibacterial activity. Oral presentation at the 222nd ACS National Meeting, Chicago, IL, August 26-30, 2001.
9. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Jakas, D. R.; Manley, P. J.; Heerding, D. A.; Takata, D. T.; Yuan, C. C. K.; Head, M. S.; Payne, D. J.; Berry, V.; Broskey, J.; Greenwood, R.; Jaworski, D. D.; Moore, T. D.; Pearson, S.; Rittenhouse, S. F.; Slater-Radosti, C.; Straub, R. J.; Van Aller, G. S.; Voelker, L. L.; Wallis, N. G.; Winram, S. B.; DeWolf, W. E., Jr.; Keller, P. M.; Polizzi, B. J.; Qiu, X.; Janson, C. A.; Chen, E.; Gorycki, P. D.; Salyers, K. L.; Bolgunas, S. P.; Cheng, H.-Y.; Geng, X. X.; Oshiro, K. K.; Jepras, R. I.; Tolson, D. A.; Vaidya, K.; Fosberry, A. P.; Smyth, M. G.; Huffman, W. F. Discovery and characterization of a novel aminopyridine-based FabI inhibitor with in vivo antibacterial activity. Poster presentation at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 16-19, 2001, Chicago, IL.
10. Miller, W. H. Discovery of small molecule inhibitors of the histone methyltransferase EZH2. Oral presentation at the NESACS Symposium on Epigenetic Targets, December 13, 2012, Waltham, MA.